Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib (MLN8237) in Advanced Nonhematological Malignancies
NCT01045421Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Feb 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alisertib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 3 more, sponsored by Millennium Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicities and Objective Response Rate. Started Feb 2010; status: completed.
02
Drugs
alisertib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)breast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01045421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01045421.